Loading
journalsJournal
PLOS Medicine
A fully open-access general medical journal that favours studies with global public-health impact, including cancer epidemiology, screening and health-policy work.
Also called: PLoS Med
Overview
Publishes under CC BY with a mandatory data-availability policy, so cancer epidemiology, risk-prediction and health-system studies here come with the underlying data. Less clinical-trial-heavy than NEJM or Lancet; strong on low- and middle-income-country cancer burden, alcohol and obesity attributable fractions, and research-integrity commentary.
Publisher
Public Library of Science
Scope
general medicine
Access model
open access
Founded
2004
ISSN
1549-1277
rct2022100 citations
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
A second publication from the STAMPEDE trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
meta analysis2013152 citations
Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis
The deprivation gradient in lung cancer is not only about who gets the disease. Among people who already have it, and at the same stage, poorer patients are less likely to be offered the treatment that works.
translational2005changed practice2,625 citations
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
It generalised the single-patient finding and made the point that drug-resistant subclones are selected by treatment rather than created by it, which is the model the whole field now works with.
Gianvito Martino
Scientific Director (Direttore Scientifico)
NeuroscienceNeuroimmunologyResearch leadership
Neurologist and neural stem cell researcher who serves as Scientific Director of IRCCS Ospedale San Raffaele in Milan.
James Brenton
Interim Deputy Director
Ovarian cancerCancer genomicsCirculating tumour DNA
Cambridge medical oncologist and Interim Deputy Director of the CRUK Cambridge Institute, a leader in ovarian cancer genomics and ctDNA monitoring.
rctPLOS Medicine 2022100 citations
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
A second publication from the STAMPEDE trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
meta analysisPLoS Medicine 2013152 citations
Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis
The deprivation gradient in lung cancer is not only about who gets the disease. Among people who already have it, and at the same stage, poorer patients are less likely to be offered the treatment that works.
translationalPLOS Medicine 2005changed practice2,625 citations
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
It generalised the single-patient finding and made the point that drug-resistant subclones are selected by treatment rather than created by it, which is the model the whole field now works with.
terms
people
key papers
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainRadiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialSocioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis